Biolife Solutions Inc. (BLFS)
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.
4 Medical Product Stocks to Buy From a Challenging Industry
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for BioLife Solutions (BLFS)
The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BioLife Looks Strong For Fiscal Year 2026
BioLife Solutions has executed a successful turnaround by refocusing on core biopreservation media and vials, divesting non-core assets. BLFS expects 17–20% revenue growth in FY26, positive GAAP net income, and mid-60s gross margins, supported by dominant CGT market share. Strategic acquisitions like PanTHERA and partnerships such as QKine are set to drive ARPU expansion and next-gen product launches by late 2026.
Wall Street Analysts Believe BioLife Solutions (BLFS) Could Rally 35%: Here's is How to Trade
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.01 per share a year ago.
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript
BioLife Solutions, Inc. ( BLFS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - CEO & Chairman Conference Call Participants Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Stanton - Jefferies LLC, Research Division Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2025 Shareholder and Analyst Conference Call.
